JPRN-jRCT2080221986未知2 期
A Randomized, Double-Blind, Phase 2 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy
适应症
试验速览
- 阶段
- 2 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Non-squamous Non-Small Cell Lung Cancer disease
- •Clinical stage IV or recurrent disease
- •One prior first-line platinum-based chemotherapy regimen with or without maintenance therapy
- •For Non-Small Cell Lung Cancer (NSCLC) tumors other than squamous cell histology, the epidermal growth factor receptor (EGFR) mutation status is known prior to randomization
- •For participants with activating epidermal growth factor receptor (EGFR) mutation ONLY, prior epidermal growth factor receptor- tyrosine kinase inhibitor (EGFR-TKI) monotherapy (only one regimen in the setting of single use) should be utilized
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
- •Measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version RECIST version 1.1
- •Adequate organ function
- •Estimated life expectancy of at least 3 months.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based TherapyEUCTR2010-021297-11-NOEli Lilly and Company Limited, Indianapolis1,253
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based TherapyEUCTR2010-021297-11-ATEli Lilly and Company Limited, Indianapolis1,242
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based TherapyStage IV Non-Small Cell Lung CancerMedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021297-11-DEEli Lilly and Company Limited, Indianapolis1,242
进行中（未招募）
1 期
A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based TherapyStage IV Non-Small Cell Lung CancerMedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021297-11-NLEli Lilly and Company Limited, Indianapolis1,242
进行中（未招募）
1 期
This study compares the already marketed drug Docetaxel together with a new, investigative drug ( Ramucirumab) in one group of patients, with Docetaxel in a second group of patients. For that purpose, the second group gets an infusion without the new drug, Ramucirumab, included (a so-called Placebo). This study is for patients with a specific lung cancer and who had received one previous chemotherapy. One compound of this previous therapy must be Cisplatin or Carboplatin.Stage IV Non-Small Cell Lung CancerMedDRA version: 14.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-021297-11-SEEli Lilly and Company Limited, Indianapolis1,242